Polar Capital Holdings Reports 5.19% Of Xenon Shares With A Passive-Control Certification
The holding company and investment adviser Polar Capital LLP each reported the same 5,022,084-share position.
Polar Capital Holdings reported Monday a 5.19% stake in Xenon Pharmaceuticals, which develops drugs for neurological and psychiatric disorders. Its SEC passive ownership disclosure put the position at 5,022,084 common shares as of September 30.
The Same Position, Two Reporting Entities
Polar Capital LLP, the investment adviser named in the disclosure, reported the same share count and ownership percentage as Polar Capital Holdings. Each entity reported sole voting power over 5,022,084 shares.
Both certified that the shares were bought and held for ordinary business purposes, without a purpose or effect of changing or influencing Xenon's control.
The ownership percentage used 96,840,432 outstanding shares, the count Xenon reported in its August 6, 2026, quarterly filing.
Azetukalner Leads Xenon's Drug Pipeline
Xenon's main experimental drug, azetukalner, is in late-stage studies for epilepsy, major depressive disorder and bipolar depression. Its earlier-stage work includes potential drugs for pain and Dravet syndrome, a form of epilepsy.
Xenon also licenses drug-development rights to Neurocrine Biosciences through a collaboration that pays milestones and royalties. Xenon received a $7.5 million milestone payment in February 2025.
As of December 31, 2025, Xenon owned, co-owned or licensed 22 issued U.S. patents and had more than 295 patent applications pending. Its market value was $4.0 billion as of 9:59 a.m. ET Monday.